Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies
出版年份 2022 全文链接
标题
Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies
作者
关键词
-
出版物
PHARMACOLOGICAL RESEARCH
Volume 187, Issue -, Pages 106631
出版商
Elsevier BV
发表日期
2022-12-29
DOI
10.1016/j.phrs.2022.106631
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
- (2022) Eric Karran et al. NATURE REVIEWS DRUG DISCOVERY
- Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques
- (2022) Ju-Hyun Lee et al. NATURE NEUROSCIENCE
- Exogenous Aβ1-42 monomers improve synaptic and cognitive function in Alzheimer's disease model mice
- (2022) Yanhong Duan et al. NEUROPHARMACOLOGY
- Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer’s Disease
- (2022) Deli Wang et al. Therapeutic Innovation & Regulatory Science
- Proteins Do Not Replicate, They Precipitate: Phase Transition and Loss of Function Toxicity in Amyloid Pathologies
- (2022) Kariem Ezzat et al. Biology-Basel
- High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer’s Disease-Causing Mutations
- (2022) Andrea Sturchio et al. JOURNAL OF ALZHEIMERS DISEASE
- Synaptogenic effect of APP -Swedish mutation in familial Alzheimer’s disease
- (2022) Bo Zhou et al. Science Translational Medicine
- Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes
- (2022) Sergey Shcherbinin et al. JAMA Neurology
- Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease
- (2022) Michael J. Pontecorvo et al. JAMA Neurology
- Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease
- (2022) Susanne Ostrowitzki et al. JAMA Neurology
- Lecanemab for Alzheimer's disease: tempering hype and hope
- (2022) The Lancet LANCET
- Alzheimer's disease
- (2021) Philip Scheltens et al. LANCET
- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
- (2021) Chad J. Swanson et al. Alzheimers Research & Therapy
- Soluble Amyloid-β Consumption in Alzheimer’s Disease
- (2021) Alberto J. Espay et al. JOURNAL OF ALZHEIMERS DISEASE
- A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
- (2021) Stephen Salloway et al. NATURE MEDICINE
- Can we learn lessons from the FDA’s approval of aducanumab?
- (2021) Kathy Y. Liu et al. Nature Reviews Neurology
- Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques
- (2021) Yan Li et al. NEUROLOGY
- FDA Drug Approval and the Ethics of Desperation
- (2021) Emily A. Largent et al. JAMA Internal Medicine
- The β-secretase BACE1 in Alzheimer’s disease
- (2020) Harald Hampel et al. BIOLOGICAL PSYCHIATRY
- The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics
- (2020) Sarah A. Kent et al. ACTA NEUROPATHOLOGICA
- The Use of Antimicrobial and Antiviral Drugs in Alzheimer’s Disease
- (2020) Umar H. Iqbal et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain
- (2020) Cyrille Sur et al. BRAIN
- Amyloid-β Immunotherapy for Alzheimer's Disease - Is It Now A Long Shot…?
- (2019) Francesco Panza et al. ANNALS OF NEUROLOGY
- A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
- (2019) Francesco Panza et al. Nature Reviews Neurology
- Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
- (2019) Michael F. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
- (2019) Michael F. Egan et al. Alzheimers Research & Therapy
- Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients?
- (2019) Francesco Panza et al. AGEING RESEARCH REVIEWS
- Investigational BACE inhibitors for the treatment of Alzheimer’s disease
- (2019) Bruno P. Imbimbo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics
- (2018) Brendan P. Lucey et al. ANNALS OF NEUROLOGY
- Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
- (2018) Michael F. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
- (2018) Lawrence S. Honig et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
- (2018) Holly M. Brothers et al. Frontiers in Aging Neuroscience
- Plasma Aβ42 as Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study
- (2018) Diego Albani et al. JOURNAL OF ALZHEIMERS DISEASE
- Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons
- (2017) Michael C. Donohue et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Amyloid-β Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory
- (2017) Agostino Palmeri et al. JOURNAL OF NEUROSCIENCE
- A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
- (2017) Susanne Ostrowitzki et al. Alzheimers Research & Therapy
- Reexamining Alzheimer's Disease: Evidence for a Protective Role for Amyloid-β Protein Precursor and Amyloid-β
- (2017) Rudy J. Castellani et al. JOURNAL OF ALZHEIMERS DISEASE
- A Physiological Role for Amyloid-β Protein: Enhancement of Learning and Memory
- (2017) John E. Morley et al. JOURNAL OF ALZHEIMERS DISEASE
- Is Brain Amyloid Production a Cause or a Result of Dementia of The Alzheimer's Type?
- (2017) Robert G. Struble et al. JOURNAL OF ALZHEIMERS DISEASE
- Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer’s Disease
- (2016) Paul B. Rosenberg et al. JOURNAL OF ALZHEIMERS DISEASE
- Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study
- (2016) Samantha C Burnham et al. LANCET NEUROLOGY
- Effects of Heart Bypass Surgery on Plasma Aβ40 and Aβ42 Levels in Infants and Young Children
- (2016) Yaoqin Hu et al. MEDICINE
- Alzheimer’s disease due to loss of function: A new synthesis of the available data
- (2016) Kasper P. Kepp PROGRESS IN NEUROBIOLOGY
- Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community
- (2016) Ronald C. Petersen et al. JAMA Neurology
- Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia
- (2015) Willemijn J. Jansen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The keystone of Alzheimer pathogenesis might be sought in Aβ physiology
- (2015) D. Puzzo et al. NEUROSCIENCE
- Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
- (2015) Rachelle S Doody et al. Alzheimers Research & Therapy
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beneficial effect of amyloid beta after controlled cortical impact
- (2013) Rebekah C. Mannix et al. BRAIN INJURY
- Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
- (2013) Stephanie JB Vos et al. LANCET NEUROLOGY
- Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
- (2013) Victor L Villemagne et al. LANCET NEUROLOGY
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
- (2013) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease
- (2013) Gaël Chételat et al. NeuroImage-Clinical
- Open-heart surgery increases cerebrospinal fluid levels of Alzheimer-associated amyloid β
- (2012) B. REINSFELT et al. ACTA ANAESTHESIOLOGICA SCANDINAVICA
- Rational heterodoxy: Cholesterol reformation of the amyloid doctrine
- (2012) Michael A. Castello et al. AGEING RESEARCH REVIEWS
- Amyloid-β Immunotherapy for Alzheimers Disease
- (2012) H.J. Fu et al. CNS & Neurological Disorders-Drug Targets
- Deciphering the mechanism underlying late-onset Alzheimer disease
- (2012) Dimitrije Krstic et al. Nature Reviews Neurology
- Is Alzheimer’s disease amyloidosis the result of a repair mechanism gone astray?
- (2011) Tyler A. Kokjohn et al. Alzheimers & Dementia
- Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
- (2011) Victor L. Villemagne et al. ANNALS OF NEUROLOGY
- Reimagining Alzheimer's Disease--An Age-Based Hypothesis
- (2010) K. Herrup JOURNAL OF NEUROSCIENCE
- Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
- (2010) Christopher C. Rowe et al. NEUROBIOLOGY OF AGING
- Decreased cerebrospinal fluid Aβ42correlates with brain atrophy in cognitively normal elderly
- (2009) Anne M. Fagan et al. ANNALS OF NEUROLOGY
- A γ-secretase inhibitor decreases amyloid-β production in the central nervous system
- (2009) Randall J. Bateman et al. ANNALS OF NEUROLOGY
- -Amyloid Monomers Are Neuroprotective
- (2009) M. L. Giuffrida et al. JOURNAL OF NEUROSCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More